Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Activity Overview

Activation of the PI3K/AKT/mTOR signaling pathway has emerged as a central driver of resistance, with—and pathway alterations or overactivation have been identified in approximately half of patients with hormone receptor-positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (mBC). The expanding availability of PI3K, AKT, and PTEN-targeted therapies offers new opportunities, but also introduces complexity in managing these malignancies.

This engaging, fast-paced, and interactive Hot Seat program will equip oncologists with a practical, evidence-based framework for integrating pathway-targeted therapies into clinical practice. Faculty will examine the latest clinical trial data, compare distinct toxicity profiles, and discuss optimal sequencing strategies and patient selection in the context of evolving treatment paradigms. Through case-based discussion and expert insight, participants will gain clarity and confidence in personalizing care for patients with advanced HR+/HER2– breast cancer.

This educational activity is an archive of the live virtual symposium held on March 23, 2026.

Target Audience

This educational activity is directed toward medical oncologists, advanced practice providers, nurses, pathologists, pharmacists, and other health care providers involved in the management of mBC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the rationale for targeting the PI3K/AKT/PTEN signaling pathway in the treatment of HR+/HER2– mBC
• Apply best practices for molecular testing to identify actionable PI3K/AKT/PTEN pathway alterations in patients with HR+/HER2– mBC
• Integrate recent clinical trial evidence into the selection and sequencing of PI3K/AKT/PTEN pathway inhibitors for patients with HR+/HER2– mBC
• Implement evidence-based strategies to prevent, recognize, and manage adverse events associated with PI3K/AKT/PTEN pathway inhibitors